Literature DB >> 23466634

Cytochrome P450 epoxygenase metabolite, 14,15-EET, protects against isoproterenol-induced cellular hypertrophy in H9c2 rat cell line.

Mandy M Y Tse1, Mona E Aboutabl, Hassan N Althurwi, Osama H Elshenawy, Ghada Abdelhamid, Ayman O S El-Kadi.   

Abstract

We have previously shown that isoproterenol-induced cardiac hypertrophy causes significant changes to cytochromes P450 (CYPs) and soluble epoxide hydrolase (sEH) gene expression. Therefore, in this study, we examined the effect of isoproterenol in H9c2 cells, and the protective effects of 14,15-EET against isoproterenol-induced cellular hypertrophy. Isoproterenol was incubated with H9c2 cells for 24 and 48 h. To determine the protective effects of 14,15-EET, H9c2 cells were incubated with isoproterenol in the absence and presence of 14,15-EET. Thereafter, the expression of hypertrophic markers and different CYP genes were determined by real time-PCR. Our results demonstrated that isoproterenol significantly increased the expression of hypertrophic marker, atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), parallel to a significant increase in cell surface area. Also, isoproterenol increased the mRNA expression of CYP1A1, CYP1B1, CYP2J3, CYP4F4 and CYP4F5, as well as the gene encoding sEH, EPHX2. On other hand, 14,15-EET significantly attenuated the isoproterenol-mediated induction of ANP, BNP, CYP1A1, CYP2J3, CYP4F4, CYP4F5 and EPHX2. Moreover 14,15-EET prevented the isoproterenol-mediated increase in cell surface area. Interestingly, 20-hydroxyeicosatetraenoic acid (20-HETE) treatment caused similar effects to that of isoproterenol treatment and induced cellular hypertrophy in H9c2 cells. In conclusion, isoproterenol induces cellular hypertrophy and modulates the expression of CYPs and EPHX2 in H9c2 cells. Furthermore, 14,15-EET exerts a protective effect against isoproterenol-induced cellular hypertrophy whereas, 20-HETE induced cellular hypertrophy in H9c2 cells.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23466634     DOI: 10.1016/j.vph.2013.02.004

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  9 in total

1.  CYP epoxygenase 2J2 prevents cardiac fibrosis by suppression of transmission of pro-inflammation from cardiomyocytes to macrophages.

Authors:  Lei Yang; Li Ni; Quanlu Duan; Xingxu Wang; Chen Chen; Song Chen; Sandip Chaugai; D C Zeldin; Jia Rong Tang; Dao Wen Wang
Journal:  Prostaglandins Other Lipid Mediat       Date:  2015-02-14       Impact factor: 3.072

2.  Star-PAP controlled alternative polyadenylation coupled poly(A) tail length regulates protein expression in hypertrophic heart.

Authors:  A P Sudheesh; Nimmy Mohan; Nimmy Francis; Rakesh S Laishram; Richard A Anderson
Journal:  Nucleic Acids Res       Date:  2019-11-18       Impact factor: 16.971

3.  The role of cytochrome P450 1B1 and its associated mid-chain hydroxyeicosatetraenoic acid metabolites in the development of cardiac hypertrophy induced by isoproterenol.

Authors:  Zaid H Maayah; Hassan N Althurwi; Ahmed A El-Sherbeni; Ghada Abdelhamid; Arno G Siraki; Ayman O S El-Kadi
Journal:  Mol Cell Biochem       Date:  2017-03-01       Impact factor: 3.396

4.  P450 Eicosanoids and Reactive Oxygen Species Interplay in Brain Injury and Neuroprotection.

Authors:  Xuehong Liu; Catherine M Davis; Nabil J Alkayed
Journal:  Antioxid Redox Signal       Date:  2017-04-20       Impact factor: 8.401

Review 5.  Clinical Implications of 20-Hydroxyeicosatetraenoic Acid in the Kidney, Liver, Lung and Brain: An Emerging Therapeutic Target.

Authors:  Osama H Elshenawy; Sherif M Shoieb; Anwar Mohamed; Ayman O S El-Kadi
Journal:  Pharmaceutics       Date:  2017-02-20       Impact factor: 6.321

6.  2-Methoxyestradiol protects against pressure overload-induced left ventricular hypertrophy.

Authors:  Zaid H Maayah; Jody Levasseur; Ramanaguru Siva Piragasam; Ghada Abdelhamid; Jason R B Dyck; Richard P Fahlman; Arno G Siraki; Ayman O S El-Kadi
Journal:  Sci Rep       Date:  2018-02-09       Impact factor: 4.379

7.  Aliskiren attenuates cardiac dysfunction by modulation of the mTOR and apoptosis pathways.

Authors:  Zhengbo Zhao; Han Liu; Dongmei Guo
Journal:  Braz J Med Biol Res       Date:  2020-01-24       Impact factor: 2.590

8.  CYP1B1 as a therapeutic target in cardio-oncology.

Authors:  Alexa N Carrera; Marianne K O Grant; Beshay N Zordoky
Journal:  Clin Sci (Lond)       Date:  2020-11-13       Impact factor: 6.124

Review 9.  The Role of Epoxyeicosatrienoic Acids in Cardiac Remodeling.

Authors:  Jinsheng Lai; Chen Chen
Journal:  Front Physiol       Date:  2021-02-24       Impact factor: 4.566

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.